Application of Chitosan-Based Nanocarriers in Tumor-Targeted Drug Delivery

Molecular Biotechnology

Volumn 57, Issue 3, 2015, Pages 201-218

  Ghaz Jahanian, Mohammad Ali ^a   Abbaspour Aghdam, Farzin ^a   Anarjan, Navideh ^b   Berenjian, Aydin ^c   Jafarizadeh Malmiri, Hoda ^a  

^a SAHAND UNIVERSITY OF TECHNOLOGY   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c UNIVERSITY OF WAIKATO   (New Zealand)

Author keywords

Chitosan; Efficacy mechanisms; Nanocarrier; Targeted drug delivery; Tumor

Indexed keywords

BIOCOMPATIBILITY; BIODEGRADABILITY; CHEMOTHERAPY; CHITOSAN; CONTROLLED DRUG DELIVERY; DISEASES; DRUG INTERACTIONS; HISTOLOGY; LIGANDS; LIPOSOMES; MICELLES; NANOPARTICLES; TUMORS;

ANTI-CANCER AGENTS; CHITOSAN NANOPARTICLES; MULTIDRUG RESISTANCE; NANOCARRIERS; POLYMERIC NANOPARTICLES; RECEPTOR INTERACTION; TUMOR-TARGETED DRUG DELIVERIES; UNDESIRABLE EFFECTS;

TARGETED DRUG DELIVERY;

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBON NANOTUBE; CHITOSAN NANOPARTICLE; CISPLATIN; DENDRIMER; DOCETAXEL; DOXORUBICIN; GLYCOL; LIGAND; LIPOSOME; MAGNETIC NANOPARTICLE; NANOCARRIER; PACLITAXEL; BIOMATERIAL; CHITOSAN; NANOPARTICLE;

BIOCOMPATIBILITY; CANCER CHEMOTHERAPY; CANCER THERAPY; CONJUGATION; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; HUMAN; HYDROPHILICITY; MICELLE; MULTIDRUG RESISTANCE; PH; PHOTODYNAMIC THERAPY; REVIEW; SOLID TUMOR; STIMULUS RESPONSE; TUMOR VASCULARIZATION; ANIMAL; CHEMISTRY; NEOPLASMS; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOCOMPATIBLE MATERIALS; CHITOSAN; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NEOPLASMS;

EID: 84923823166     PISSN: 10736085     EISSN: 15590305     Source Type: Journal    
DOI: 10.1007/s12033-014-9816-3     Document Type: Review

References (112)

1. Sarkar, F. H., Banerjee, S., & Li, Y. (2007). Pancreatic cancer: Pathogenesis, prevention and treatment. Toxicology and Applied Pharmacology,224, 326–336.
2. Byrne, J. D., Betancourt, T., & Brannon-Peppas, L. (2008). Active targeting schemes for nanoparticle systems in cancer therapeutics. Advanced Drug Delivery Reviews,60, 1615–1626.
3. Manchun, S., Dass, C. R., & Sriamornsak, P. (2012). Targeted therapy for cancer using pH-responsive nanocarrier systems. Life Sciences,90, 381–387.
4. Patel, N. R., Pattni, B. S., Abouzeid, A. H., & Torchilin, V. P. (2013). Nanopreparations to overcome multidrug resistance in cancer. Advanced Drug Delivery Reviews,65, 1748–1762.
5. Chan, A., Orme, R. P., Fricker, R. A., & Roach, P. (2013). Remote and local control of stimuli responsive materials for therapeutic applications. Advanced Drug Delivery Reviews,65, 497–514.
6. Pulkkinen, M., Pikkarainen, J., Wirth, T., Tarvainen, T., Haapa-aho, V., Korhonen, H., et al. (2008). Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin–biotin technology: Formulation development and in vitro anticancer activity. European Journal of Pharmaceutics and Biopharmaceutics,70, 66–74.
7. Sanoj Rejinold, N., Sreerekha, P. R., Chennazhi, K. P., Nair, S. V., & Jayakumar, R. (2011). Biocompatible, biodegradable and thermo-sensitive chitosan-g-poly (N-isopropylacrylamide) nanocarrier for curcumin drug delivery. International Journal of Biological Macromolecules,49, 161–172.
8. Lakshmanan, V.-K., Snima, K. S., Bumgardner, J., Nair, S., & Jayakumar, R. (2011). Chitosan-based nanoparticles in cancer therapy. In R. Jayakumar, M. Prabaharan, & R. A. A. Muzzarelli (Eds.), Chitosan for biomaterials, vol. 243: Advances in polymer science (pp. 55–91). Berlin: Springer.
9. Liu, Z., Jiao, Y., Wang, Y., Zhou, C., & Zhang, Z. (2008). Polysaccharides-based nanoparticles as drug delivery systems. Advanced Drug Delivery Reviews,60, 1650–1662.
10. Torchilin, V. P. (2004). Targeted polymeric micelles for delivery of poorly soluble drugs. CMLS. Cellular and Molecular Life Sciences,61, 2549–2559.
11. Park, J. H., Saravanakumar, G., Kim, K., & Kwon, I. C. (2010). Targeted delivery of low molecular drugs using chitosan and its derivatives. Advanced Drug Delivery Reviews,62, 28–41.
12. Thanki, K., Gangwal, R. P., Sangamwar, A. T., & Jain, S. (2013). Oral delivery of anticancer drugs: Challenges and opportunities. Journal of Controlled Release,170, 15–40.
13. Wang, M. D., Shin, D. M., Simons, J. W., & Nie, S. (2007). Nanotechnology for targeted cancer therapy. Expert Review of Anticancer Therapy 7, 833–837.
14. Jabr-Milane, L. S., van Vlerken, L. E., Yadav, S., & Amiji, M. M. (2008). Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treatment Reviews,34, 592–602.
15. Venkatesan, P., Puvvada, N., Dash, R., Prashanth Kumar, B. N., Sarkar, D., Azab, B., et al. (2011). The potential of celecoxib-loaded hydroxyapatite-chitosan nanocomposite for the treatment of colon cancer. Biomaterials,32, 3794–3806.
16. He, M., Zhao, Z., Yin, L., Tang, C., & Yin, C. (2009). Hyaluronic acid coated poly(butyl cyanoacrylate) nanoparticles as anticancer drug carriers. International Journal of Pharmaceutics,373, 165–173.
17. Jee, J.-P., Na, J. H., Lee, S., Kim, S. H., Choi, K., Yeo, Y., et al. (2012). Cancer targeting strategies in nanomedicine: Design and application of chitosan nanoparticles. Current Opinion in Solid State and Materials Science,16, 333–342.
18. Bates, D. O., Hillman, N. J., Williams, B., Neal, C. R., & Pocock, T. M. (2002). Regulation of microvascular permeability by vascular endothelial growth factors*. Journal of Anatomy,200, 581–597.
19. Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014). Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. Advanced Drug Delivery Reviews,66, 2–25.
20. Brannon-Peppas, L., & Blanchette, J. O. (2004). Nanoparticle and targeted systems for cancer therapy. Advanced Drug Delivery Reviews,56, 1649–1659.
21. Torchilin, V. (2011). Tumor delivery of macromolecular drugs based on the EPR effect. Advanced Drug Delivery Reviews,63, 131–135.
22. Koo, H., Min, K. H., Lee, S. C., Park, J. H., Park, K., Jeong, S. Y., et al. (2013). Enhanced drug-loading and therapeutic efficacy of hydrotropic oligomer-conjugated glycol chitosan nanoparticles for tumor-targeted paclitaxel delivery. Journal of Controlled Release,172, 823–831.
23. Yin, Q., Shen, J., Zhang, Z., Yu, H., & Li, Y. (2013). Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor. Advanced Drug Delivery Reviews,65, 1699–1715.
24. Livney, Y. D., & Assaraf, Y. G. (2013). Rationally designed nanovehicles to overcome cancer chemoresistance. Advanced Drug Delivery Reviews,65, 1716–1730.
25. Jin, Y.-H., Hu, H.-Y., Qiao, M.-X., Zhu, J., Qi, J.-W., Hu, C.-J., et al. (2012). pH-Sensitive chitosan-derived nanoparticles as doxorubicin carriers for effective anti-tumor activity: preparation and in vitro evaluation. Colloids and Surfaces B,94, 184–191.
26. Mohamed, S., Zeino, M., Kadioglu, O., Volm, M., & Efferth, T. (2014). Overcoming of P-glycoprotein-mediated multidrug resistance of tumors in vivo by drug combinations. Synergy,1, 44–58.
27. Shapira, A., Livney, Y. D., Broxterman, H. J., & Assaraf, Y. G. (2011). Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance. Drug Resistance Updates,14, 150–163.
28. Garbuzenko, O. B., Saad, M., Pozharov, V. P., Reuhl, K. R., Mainelis, G., & Minko, T. (2010). Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. In Proceedings of the National Academy of Sciences.
29. Oh, N. M., Oh, K. T., Baik, H. J., Lee, B. R., Lee, A. H., Youn, Y. S., et al. (2010). A self-organized 3-diethylaminopropyl-bearing glycol chitosan nanogel for tumor acidic pH targeting: In vitro evaluation. Colloids and Surfaces B,78, 120–126.
30. Saraswathy, M., & Gong, S. (2013). Different strategies to overcome multidrug resistance in cancer. Biotechnology Advances,13, 1397–1407.
31. Palakurthi, S., Yellepeddi, V. K., & Vangara, K. K. (2012). Recent trends in cancer drug resistance rever-sal strategies using nanoparticles. Expert opinion on drug delivery,9, 287–301.
32. Choi, K. Y., Chung, H., Min, K. H., Yoon, H. Y., Kim, K., Park, J. H., et al. (2010). Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials,31, 106–114.
33. Lee, S. J., Koo, H., Jeong, H., Huh, M. S., Choi, Y., Jeong, S. Y., et al. (2011). Comparative study of photosensitizer loaded and conjugated glycol chitosan nanoparticles for cancer therapy. Journal of Controlled Release,152, 21–29.
34. Fahr, A., & Liu, X. (2007). Drug delivery strategies for poorly water-soluble drugs. Expert opinion on drug delivery,4, 403–416.
35. Huo, M., Zhang, Y., Zhou, J., Zou, A., Yu, D., Wu, Y., et al. (2010). Synthesis and characterization of low-toxic amphiphilic chitosan derivatives and their application as micelle carrier for antitumor drug. International Journal of Pharmaceutics,394, 162–173.
36. Fan, L., Li, F., Zhang, H., Wang, Y., Cheng, C., Li, X., et al. (2010). Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance. Biomaterials,31, 5634–5642.
37. Min, K. H., Park, K., Kim, Y.-S., Bae, S. M., Lee, S., Jo, H. G., et al. (2008). Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. Journal of Controlled Release,127, 208–218.
38. Gao, J., Ming, J., He, B., Fan, Y., Gu, Z., & Zhang, X. (2008). Preparation and characterization of novel polymeric micelles for 9-nitro-20(S)-camptothecin delivery. European Journal of Pharmaceutical Sciences,34, 85–93.
39. Ye, Y.-Q., Chen, F.-Y., Wu, Q.-A., Hu, F.-Q., Du, Y.-Z., Yuan, H., et al. (2009). Enhanced cytotoxicity of core modified chitosan based polymeric micelles for doxorubicin delivery. Journal of Pharmaceutical Sciences,98, 704–712.
40. Torchilin, V. P. (2000). Drug targeting. European Journal of Pharmaceutical Sciences,11(Supplement 2), S81–S91.
41. Ranganathan, R., Madanmohan, S., Kesavan, A., Baskar, G., Krishnamoorthy, Y. R., Santosham, R., et al. (2012). Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications. International Journal of Nanomedicine,7, e1060.
42. Altintas, I., Kok, R. J., & Schiffelers, R. M. (2012). Targeting epidermal growth factor receptor in tumors: From conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies. European Journal of Pharmaceutical Sciences,45, 399–407.
43. Torchilin, V. (2009). Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. European Journal of Pharmaceutics and Biopharmaceutics,71, 431–444.
44. Sun, Q., Radosz, M., & Shen, Y. (2012). Challenges in design of translational nanocarriers. Journal of Controlled Release,164, 156–169.
45. Florence, A. T. (2007). Pharmaceutical nanotechnology: More than size: Ten topics for research. International Journal of Pharmaceutics,339, 1–2.
46. Kong, M., Park, H., Cheng, X., & Chen, X. (2013). Spatial–temporal event adaptive characteristics of nanocarrier drug delivery in cancer therapy. Journal of Controlled Release,172, 281–291.
47. Kwon, I. K., Lee, S. C., Han, B., & Park, K. (2012). Analysis on the current status of targeted drug delivery to tumors. Journal of Controlled Release,164, 108–114.
48. Yameen, B., Choi, W., Vilos, C., Swami, A., Shi, J., & Farokhzad, O. (2014). Insight into nanoparticle cellular uptake and intracellular targeting. Controlled Release,190, 485–499.
49. Bae, Y. H., & Park, K. (2011). Targeted drug delivery to tumors: Myths, reality and possibility. Journal of Controlled Release,153, 198–205.
50. Maeda, H., Bharate, G. Y., & Daruwalla, J. (2009). Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. European Journal of Pharmaceutics and Biopharmaceutics,71, 409–419.
51. Hudson, D., & Margaritis, A. (2013). Biopolymer nanoparticle production for controlled release of biopharmaceuticals. Critical Reviews in Biotechnology,0, 1–19.
52. Kumari, A., Yadav, S. K., & Yadav, S. C. (2010). Biodegradable polymeric nanoparticles based drug delivery systems. Colloids and Surfaces B,75, 1–18.
53. Duceppe, N., & Tabrizian, M. (2010). Advances in using chitosan-based nanoparticles for in vitro and in vivo drug and gene delivery. Expert opinion on drug delivery,7, 1191–1207.
54. Rai, P., Mallidi, S., Zheng, X., Rahmanzadeh, R., Mir, Y., Elrington, S., et al. (2010). Development and applications of photo-triggered theranostic agents. Advanced Drug Delivery Reviews,62, 1094–1124.
55. Gulbake, A., & Jain, S. K. (2012). Chitosan: A potential polymer for colon-specific drug delivery system. Expert opinion on drug delivery,9, 713–729.
56. Ashkenazi, A. (2002). Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nature Reviews Cancer,2, 420–430.
57. Riva, R., Ragelle, H., Rieux, A., Duhem, N., Jérôme, C., & Préat, V. (2011). Chitosan and chitosan derivatives in drug delivery and tissue engineering. In R. Jayakumar, M. Prabaharan, & R. A. A. Muzzarelli (Eds.), Chitosan for biomaterials II, vol. 244: Advances in polymer science (pp. 19–44). Berlin: Springer.
58. Liu, J., Li, H., Jiang, X., Zhang, C., & Ping, Q. (2010). Novel pH-sensitive chitosan-derived micelles loaded with paclitaxel. Carbohydrate Polymers,82, 432–439.
59. Nogueira, D. R., Tavano, L., Mitjans, M., Pérez, L., Infante, M. R., & Vinardell, M. P. (2013). In vitro antitumor activity of methotrexate via pH-sensitive chitosan nanoparticles. Biomaterials,34, 2758–2772.
60. Derakhshandeh, K., & Fathi, S. (2012). Role of chitosan nanoparticles in the oral absorption of Gemcitabine. International Journal of Pharmaceutics,437, 172–177.
61. Garg, N. K., Dwivedi, P., Campbell, C., & Tyagi, R. K. (2012). Site specific/targeted delivery of gemcitabine through anisamide anchored chitosan/poly ethylene glycol nanoparticles: An improved understanding of lung cancer therapeutic intervention. European Journal of Pharmaceutical Sciences,47, 1006–1014.
62. Arya, G., Vandana, M., Acharya, S., & Sahoo, S. K. (2011). Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy. Nanomedicine,7, 859–870.
63. Anitha, A., Maya, S., Deepa, N., Chennazhi, K. P., Nair, S. V., Tamura, H., et al. (2011). Efficient water soluble O-carboxymethyl chitosan nanocarrier for the delivery of curcumin to cancer cells. Carbohydrate Polymers,83, 452–461.
64. Zhang, C., Qu, G., Sun, Y., Yang, T., Yao, Z., Shen, W., et al. (2008). Biological evaluation of N-octyl-O-sulfate chitosan as a new nano-carrier of intravenous drugs. European Journal of Pharmaceutical Sciences,33, 415–423.
65. Zhang, C., Qineng, P., & Zhang, H. (2004). Self-assembly and characterization of paclitaxel-loaded N-octyl-O-sulfate chitosan micellar system. Colloids and Surfaces B,39, 69–75.
66. Deckert, P. (2009). Current constructs and targets in clinical development for antibody-based cancer therapy. Current Drug Targets,10, 158–175.
67. Malmiri, H. J., Jahanian, M. A. G., & Berenjian, A. (2012). Potential applications of chitosan nanoparticles as novel support in enzyme immobilization. American Journal of Biochemistry & Biotechnology, 8, 203–219.
68. Folkes, L. K., & Wardman, P. (2003). Enhancing the efficacy of photodynamic cancer therapy by radicals from plant auxin (indole-3-acetic acid). Cancer Research,63, 776–779.
69. Yuan, Q., Venkatasubramanian, R., Hein, S., & Misra, R. D. K. (2008). A stimulus-responsive magnetic nanoparticle drug carrier: Magnetite encapsulated by chitosan-grafted-copolymer. Acta Biomaterialia,4, 1024–1037.
70. Razmi, M., Divsalar, A., Saboury, A. A., Izadi, Z., Haertlé, T., & Mansuri-Torshizi, H. (2013). Beta-casein and its complexes with chitosan as nanovehicles for delivery of a platinum anticancer drug. Colloids and Surfaces B,112, 362–367.
71. Arias, J. L., López-Viota, M., Sáez-Fernández, E., Ruiz, M. A., & Delgado, Á. V. (2011). Engineering of an antitumor (core/shell) magnetic nanoformulation based on the chemotherapy agent ftorafur. Colloids and Surfaces A,384, 157–163.
72. Unsoy, G., Yalcin, S., Khodadust, R., Mutlu, P., Onguru, O., & Gunduz, U. (2014). Chitosan magnetic nanoparticles for pH responsive Bortezomib release in cancer therapy. Biomedicine & Pharmacotherapy. doi:10.1016/j.biopha.2014.04.003.
73. Feng, C., Wang, Z., Jiang, C., Kong, M., Zhou, X., Li, Y., et al. (2013). Chitosan/o-carboxymethyl chitosan nanoparticles for efficient and safe oral anticancer drug delivery: In vitro and in vivo evaluation. International Journal of Pharmaceutics,457, 158–167.
74. Mura, S., Nicolas, J., & Couvreur, P. (2013). Stimuli-responsive nanocarriers for drug delivery. Nature Materials,12, 991–1003.
75. Zhou, N., Zan, X., Wang, Z., Wu, H., Yin, D., Liao, C., et al. (2013). Galactosylated chitosan–polycaprolactone nanoparticles for hepatocyte-targeted delivery of curcumin. Carbohydrate Polymers,94, 420–429.
76. Huo, M., Zou, A., Yao, C., Zhang, Y., Zhou, J., Wang, J., et al. (2012). Somatostatin receptor-mediated tumor-targeting drug delivery using octreotide-PEG-deoxycholic acid conjugate-modified N-deoxycholic acid-O, N-hydroxyethylation chitosan micelles. Biomaterials,33, 6393–6407.
77. Park, E. K., Lee, S. B., & Lee, Y. M. (2005). Preparation and characterization of methoxy poly(ethylene glycol)/poly(ε-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs. Biomaterials,26, 1053–1061.
78. Chan, P., Kurisawa, M., Chung, J. E., & Yang, Y.-Y. (2007). Synthesis and characterization of chitosan-g-poly(ethylene glycol)-folate as a non-viral carrier for tumor-targeted gene delivery. Biomaterials,28, 540–549.
79. Yang, S.-J., Lin, F.-H., Tsai, K.-C., Wei, M.-F., Tsai, H.-M., Wong, J.-M., et al. (2010). Folic acid-conjugated chitosan nanoparticles enhanced protoporphyrin IX accumulation in colorectal cancer cells. Bioconjugate Chemistry,21, 679–689.
80. Guillermet-Guibert, J., Lahlou, H., Cordelier, P., Bousquet, C., Pyronnet, S., & Susini, C. (2005). Physiology of somatostatin receptors. Journal of Endocrinological Investigation,28, 5.
81. Mariniello, B., Finco, I., Sartorato, P., Patalano, A., Iacobone, M., Guzzardo, V., et al. (2011). Somatostatin receptor expression in adrenocortical tumors and effect of a new somatostatin analog SOM230 on hormone secretion in vitro and in ex vivo adrenal cells. Journal of Endocrinological Investigation,34, e131–e138.
82. Guan, M., Zhou, Y., Zhu, Q.-L., Liu, Y., Bei, Y.-Y., Zhang, X.-N., et al. (2012). N-trimethyl chitosan nanoparticle-encapsulated lactosyl-norcantharidin for liver cancer therapy with high targeting efficacy. Nanomedicine,8, 1172–1181.
83. Yang, K., Kong, M., Wei, Y., Liu, Y., Cheng, X., Li, J., et al. (2013). Folate-modified–chitosan-coated liposomes for tumor-targeted drug delivery. Journal of Materials Science,48, 1717–1728.
84. Fukumura, D., & Jain, R. K. (2007). Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization. Microvascular Research,74, 72–84.
85. Pouyssegur, J., Dayan, F., & Mazure, N. M. (2006). Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature,441, 437–443.
86. Deng, Z., Zhen, Z., Hu, X., Wu, S., Xu, Z., & Chu, P. K. (2011). Hollow chitosan–silica nanospheres as pH-sensitive targeted delivery carriers in breast cancer therapy. Biomaterials,32, 4976–4986.
87. Wu, W., Shen, J., Banerjee, P., & Zhou, S. (2010). Chitosan-based responsive hybrid nanogels for integration of optical pH-sensing, tumor cell imaging and controlled drug delivery. Biomaterials,31, 8371–8381.
88. Sun, G., Zhang, X.-Z., & Chu, C.-C. (2007). Formulation and characterization of chitosan-based hydrogel films having both temperature and pH sensitivity. Journal of Materials Science. Materials in Medicine,18, 1563–1577.
89. Danhier, F., Feron, O., & Préat, V. (2010). To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of Controlled Release,148, 135–146.
90. Alarcon, C.d. l. H., Pennadam, S., & Alexander, C. (2005). Stimuli responsive polymers for biomedical applications. Chemical Society Reviews,34, 276–285.
91. Twaites, B., de las Heras Alarcon, C., & Alexander, C. (2005). Synthetic polymers as drugs and therapeutics. Journal of Materials Chemistry,15, 441–455.
92. Rejinold, N. S., Chennazhi, K. P., Nair, S. V., Tamura, H., & Jayakumar, R. (2011). Biodegradable and thermo-sensitive chitosan-g-poly(N-vinylcaprolactam) nanoparticles as a 5-fluorouracil carrier. Carbohydrate Polymers,83, 776–786.
93. Hilger, I., Hiergeist, R., Hergt, R., Winnefeld, K., Schubert, H., & Kaiser, W. A. (2002). Thermal ablation of tumors using magnetic nanoparticles: an in vivo feasibility study. Investigative Radiology,37, 580–586.
94. Pradhan, P., Giri, J., Rieken, F., Koch, C., Mykhaylyk, O., Döblinger, M., et al. (2010). Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy. Journal of Controlled Release,142, 108–121.
95. Hassan, E. E., & Gallo, J. M. (1993). Targeting anticancer drugs to the brain. I: Enhanced brain delivery of oxantrazole following administration in magnetic cationic microspheres. Journal of Drug Targeting,1, 7–14.
96. Klostergaard, J., & Seeney, C. E. (2012). Magnetic nanovectors for drug delivery. Maturitas,73, 33–44.
97. Lee, S. J., Koo, H., Lee, D.-E., Min, S., Lee, S., Chen, X., et al. (2011). Tumor-homing photosensitizer-conjugated glycol chitosan nanoparticles for synchronous photodynamic imaging and therapy based on cellular on/off system. Biomaterials,32, 4021–4029.
98. Oh, I.-H., Min, H. S., Li, L., Tran, T. H., Lee, Y.-K., Kwon, I. C., et al. (2013). Cancer cell-specific photoactivity of pheophorbide a–glycol chitosan nanoparticles for photodynamic therapy in tumor-bearing mice. Biomaterials,34, 6454–6463.
99. Goodwin, A. P., Mynar, J. L., Ma, Y., Fleming, G. R., & Fréchet, J. M. J. (2005). Synthetic micelle sensitive to IR light via a two-photon process. Journal of the American Chemical Society,127, 9952–9953.
100. Jiang, J., Tong, X., Morris, D., & Zhao, Y. (2006). Toward photocontrolled release using light-dissociable block copolymer micelles. Macromolecules,39, 4633–4640.
101. Chin, W. W. L., Heng, P. W. S., Thong, P. S. P., Bhuvaneswari, R., Hirt, W., Kuenzel, S., et al. (2008). Improved formulation of photosensitizer chlorin e6 polyvinylpyrrolidone for fluorescence diagnostic imaging and photodynamic therapy of human cancer. European Journal of Pharmaceutics and Biopharmaceutics,69, 1083–1093.
102. Lovell, J. F., Chen, J., Jarvi, M. T., Cao, W.-G., Allen, A. D., Liu, Y., et al. (2009). FRET quenching of photosensitizer singlet oxygen generation. The Journal of Physical Chemistry B,113, 3203–3211.
103. Zhang, D., Sun, P., Li, P., Xue, A., Zhang, X., Zhang, H., et al. (2013). A magnetic chitosan hydrogel for sustained and prolonged delivery of Bacillus Calmette–Guérin in the treatment of bladder cancer. Biomaterials,34, 10258–10266.
104. Chang, Y.-C., Shieh, D.-B., Chang, C.-H., & Chen, D.-H. (2005). Conjugation of monodisperse chitosan-bound magnetic nanocarrier with epirubicin for targeted cancer therapy. Journal of Biomedical Nanotechnology,1, 196–201.
105. Rajan, M., Raj, V., Al-Arfaj, A. A., & Murugan, A. M. (2013). Hyaluronidase enzyme core-5-fluorouracil-loaded chitosan-PEG-gelatin polymer nanocomposites as targeted and controlled drug delivery vehicles. International Journal of Pharmaceutics,453, 514–522.
106. Puga, A. M., Lima, A. C., Mano, J. F., Concheiro, A., & Alvarez-Lorenzo, C. (2013). Pectin-coated chitosan microgels crosslinked on superhydrophobic surfaces for 5-fluorouracil encapsulation. Carbohydrate Polymers,98, 331–340.
107. Vega-Villa, K. R., Takemoto, J. K., Yáñez, J. A., Remsberg, C. M., Forrest, M. L., & Davies, N. M. (2008). Clinical toxicities of nanocarrier systems. Advanced Drug Delivery Reviews,60, 929–938.
108. Gupta, A. K., & Gupta, M. (2005). Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials,26, 3995–4021.
109. Jokerst, J. V., Lobovkina, T., Zare, R. N., & Gambhir, S. S. (2011). Nanoparticle PEGylation for imaging and therapy. Nanomedicine,6, 715–728.
110. Mebius, R. E., & Kraal, G. (2005). Structure and function of the spleen. Nature Reviews Immunology,5, 606–616.
111. Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007). Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology,2, 751–760.
112. Berenjian, A., Ghasemi, M. R., & Zarghi, A. (2011). Preparation of barium sulfate nanoparticles using semi-batch precipitation. Asian Journal of Chemistry,23, 491–494.